256 related articles for article (PubMed ID: 33822655)
1. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
[TBL] [Abstract][Full Text] [Related]
2. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.
Beyer J; Collette L; Sauvé N; Daugaard G; Feldman DR; Tandstad T; Tryakin A; Stahl O; Gonzalez-Billalabeitia E; De Giorgi U; Culine S; de Wit R; Hansen AR; Bebek M; Terbuch A; Albany C; Hentrich M; Gietema JA; Negaard H; Huddart RA; Lorch A; Cafferty FH; Heng DYC; Sweeney CJ; Winquist E; Chovanec M; Fankhauser C; Stark D; Grimison P; Necchi A; Tran B; Heidenreich A; Shamash J; Sternberg CN; Vaughn DJ; Duran I; Bokemeyer C; Patrikidou A; Cathomas R; Assele S; Gillessen S;
J Clin Oncol; 2021 May; 39(14):1553-1562. PubMed ID: 33729863
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
4. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
5. A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.
Necchi A; Pond GR; Nicolai N; Giannatempo P; Raggi D; Adra N; Hanna NH; Salvioni R; Einhorn LH; Albany C
Clin Genitourin Cancer; 2017 Apr; 15(2):306-312.e3. PubMed ID: 27594554
[TBL] [Abstract][Full Text] [Related]
6. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
[TBL] [Abstract][Full Text] [Related]
7. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
Huddart RA; Gabe R; Cafferty FH; Pollock P; White JD; Shamash J; Cullen MH; Stenning SP; ;
Eur Urol; 2015 Mar; 67(3):534-43. PubMed ID: 25001888
[TBL] [Abstract][Full Text] [Related]
8. Improved survival in metastatic germ-cell cancer.
Fankhauser CD; Sander S; Roth L; Beyer J; Hermanns T
Ann Oncol; 2018 Feb; 29(2):347-351. PubMed ID: 29161363
[TBL] [Abstract][Full Text] [Related]
9. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
Bührer E; D'Haese D; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Collette L; Gillessen S; Beyer J
Eur J Cancer; 2024 May; 202():114042. PubMed ID: 38564927
[TBL] [Abstract][Full Text] [Related]
10. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).
Culine S; Kerbrat P; Kramar A; Théodore C; Chevreau C; Geoffrois L; Bui NB; Pény J; Caty A; Delva R; Biron P; Fizazi K; Bouzy J; Droz JP;
Ann Oncol; 2007 May; 18(5):917-24. PubMed ID: 17351252
[TBL] [Abstract][Full Text] [Related]
11. A population-based validation of the IGCCCG Update Consortium for survival in metastatic non-seminoma testis cancer.
Incesu RB; Morra S; Scheipner L; Barletta F; Baudo A; Garcia CC; Tappero S; Piccinelli ML; Tian Z; Saad F; Shariat SF; de Cobelli O; Terrone C; Chun FKH; Carmignani L; Briganti A; Ahyai S; Longo N; Tilki D; Graefen M; Karakiewicz PI
Jpn J Clin Oncol; 2024 May; 54(5):592-598. PubMed ID: 38369557
[TBL] [Abstract][Full Text] [Related]
12. Improved outcomes in metastatic germ cell cancer: results from a large cohort study.
Hentrich M; Debole J; Jurinovic V; Gerl A
J Cancer Res Clin Oncol; 2021 Feb; 147(2):533-538. PubMed ID: 32772232
[TBL] [Abstract][Full Text] [Related]
13. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.
Fizazi K; Oldenburg J; Dunant A; Chen I; Salvioni R; Hartmann JT; De Santis M; Daugaard G; Flechon A; de Giorgi U; Tjulandin S; Schmoll HJ; Bouzy J; Fossa SD; Fromont G
Ann Oncol; 2008 Feb; 19(2):259-64. PubMed ID: 18042838
[TBL] [Abstract][Full Text] [Related]
14. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
[TBL] [Abstract][Full Text] [Related]
15. Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy.
Shamash J; Mee M; Sarker SJ; Wilson P; Ansell W; Greenwood M; Berney D; Alifrangis C
BJU Int; 2020 Jun; 125(6):843-852. PubMed ID: 31688976
[TBL] [Abstract][Full Text] [Related]
16. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial.
Fizazi K; Do KA; Wang X; Finn L; Logothetis CJ; Amato RJ
Ann Oncol; 2002 Jan; 13(1):125-34. PubMed ID: 11863094
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil.
Vasconcellos VF; Bastos DA; Pereira AAL; Watarai GY; Pereira BR; de Godoy A; Almeida-Silva J; Muniz DQB; Guglielmetti GB; Nahas WC; Dzik C
J Glob Oncol; 2019 Feb; 5():1-8. PubMed ID: 30779600
[TBL] [Abstract][Full Text] [Related]
19. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.
Antonelli L; Ardizzone D; Ravi P; Bagrodia A; Mego M; Daneshmand S; Nicolai N; Nazzani S; Giannatempo P; Franza A; Heidenreich A; Paffenholz P; Saoud R; Eggener S; Ho M; Oswald N; Olson K; Tryakin A; Fedyanin M; Naoun N; Javaud C; Fizazi K; King JM; Adra N; Douglawi A; Cary C; Sweeney C; Fankhauser CD
Eur J Cancer; 2023 Mar; 182():144-154. PubMed ID: 36787661
[TBL] [Abstract][Full Text] [Related]
20. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.
Ribnikar D; Stukalin I; Bedard PL; Hamilton RJ; Jewett M; Warde P; Chung P; Anson-Cartwright L; Templeton AJ; Amir E; Hansen AR; Heng DYC; Lewin J
Curr Oncol; 2020 Dec; 28(1):107-114. PubMed ID: 33622996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]